@article{3dc3c98a5f1046fab84be6373886621c,
title = "A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis",
abstract = "N/A",
keywords = "Antibodies, Monoclonal, Humans, Psoriasis, Severity of Illness Index, Antibodies, Monoclonal, Humans, Psoriasis, Severity of Illness Index",
author = "K. Hansel and A. Zangrilli and L. Bianchi and Ketty Peris and Andrea Chiricozzi and A. Offidani and F. Diotallevi and Fargnoli, \{M. C.\} and M. Esposito and P. Amerio and G. Gualdi and L. Bianchi and L. Stingeni",
year = "2022",
doi = "10.1111/jdv.17656",
language = "English",
volume = "36",
pages = "e111--e113",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "John Wiley and Sons Inc.",
}